Filing Summary
Business Context and Reporting Period
Cullinan Management, Inc. filed this Form 8-K on February 23, 2021, with the earliest reported event occurring on that date. The filing concerns a corporate name change and related charter and bylaw amendments. The filing identifies the registrant as Cullinan Oncology, Inc.; the provided metadata refers to Cullinan Therapeutics, Inc.
Corporate Action and Key Information
- The company filed a Certificate of Amendment to change its corporate name to Cullinan Oncology, Inc.
- The name change and amended charter became effective at 5:00 p.m. Eastern Time on February 25, 2021.
- The company adopted Second Amended and Restated Bylaws effective February 25, 2021. The filing states that the bylaws contain no other changes.
- The common stock began trading under the new company name on Nasdaq at the start of trading on February 26, 2021.
- The ticker symbol remained CGEM, and the CUSIP did not change.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating metrics, or other financial results.
Material Changes, Outlook, and Risks
The material change reported is the corporate name change and related governance-document updates. The filing provides no financial guidance, operating outlook, management commentary, risk-factor update, contingency, or unusual financial item.
Important Facts to Verify
- Confirm the effective timing of the name change: 5:00 p.m. Eastern Time on February 25, 2021.
- Confirm that trading under the new name began February 26, 2021, while the ticker remained CGEM.
- Review Exhibits 3.1 and 3.2 for the filed charter amendment and amended bylaws.
- Reconcile the company name in external records, because the filing identifies the registrant as Cullinan Oncology, Inc., while the request metadata names Cullinan Therapeutics, Inc.